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Abstract
Background: Studies suggest that anticholinergic medication or benzodiazepine use could increase dementia risk.
We tested this hypothesis using data from a UK cohort study.
Methods: We used data from the baseline (Y0), 2-year (Y2) and 10-year (Y10) waves of the Medical Research Council
Cognitive Function and Ageing Study. Participants without dementia at Y2 were included (n = 8216). Use of
benzodiazepines (including nonbenzodiazepine Z-drugs), anticholinergics with score 3 (ACB3) and anticholinergics
with score 1 or 2 (ACB12) according to the Anticholinergic Cognitive Burden scale were coded as ever use (use at Y0
or Y2), recurrent use (Y0 and Y2), new use (Y2, but not Y0) or discontinued use (Y0, but not Y2). The outcome was
incident dementia by Y10. Incidence rate ratios (IRR) were estimated using Poisson regression adjusted for potential
confounders. Pre-planned subgroup analyses were conducted by age, sex and Y2 Mini-Mental State Examination
(MMSE) score.
Results: Dementia incidence was 9.3% (N = 220 cases) between Y2 and Y10. The adjusted IRRs (95%CI) of developing
dementia were 1.06 (0.72, 1.60), 1.28 (0.82, 2.00) and 0.89 (0.68, 1.17) for benzodiazepines, ACB3 and ACB12 ever-users
compared with non-users. For recurrent users the respective IRRs were 1.30 (0.79, 2.14), 1.68 (1.00, 2.82) and 0.95 (0.71,
1.28). ACB3 ever-use was associated with dementia among those with Y2 MMSE> 25 (IRR = 2.28 [1.32–3.92]), but not if
Y2 MMSE≤25 (IRR = 0.94 [0.51–1.73]).
Conclusions: Neither benzodiazepines nor ACB12 medications were associated with dementia. Recurrent use of ACB3
anticholinergics was associated with dementia, particularly in those with good baseline cognitive function. The long-
term prescribing of anticholinergics should be avoided in older people.
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Background
Dementia prevention is a public health priority. No dis-
ease modifying treatment for dementia exists, but
dementia risk and progression can be modified by chan-
ging exposure to risk factors affecting any aspect of
long-term brain health [1]. Identifying such risk factors
is important for dementia prevention and cognitive
health.
Long-term use of several classes of medications have
been suggested to increase future dementia risk. Medica-
tions with anticholinergic activity (henceforth anticholin-
ergics), benzodiazepines and related non-benzodiazepine
derivatives have come under particular scrutiny owing to
their well-known short-term cognitive effects [2] and the
high prevalence of their long-term use among middle
aged and older people [3, 4].
Anticholinergics are successfully used in the treatment
of many conditions such as urinary incontinence, Parkin-
son’s disease, depression, and epilepsy. Anticholinergics
can adversely affect cognition [2]; guidelines suggest they
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are to be avoided among frail older people [5] or those
with dementia [6]. Over the past decade, prolonged expos-
ure to anticholinergics has been linked to long term cogni-
tive decline or dementia [7–12]. Many medicines beyond
those typically regarded as anticholinergics may have mild
anticholinergic effects and it has been suggested that the
cumulative long term use of many such medications may
increase dementia risk [11]. Depending on their definition,
anticholinergic medications are used by 10–50% of the
middle aged and older population at any time [13, 14].
Benzodiazepines and non-benzodiazepine derivatives
are primarily used to treat anxiety or insomnia. Short
term cognitive effects due to their sedating action are
well recognised. Although long-term use is not recom-
mended many people use regularly benzodiazepines and
related medicines for years or decades [3]. Estimates of
the effect of benzodiazepine use on long term cognitive
decline and dementia have been mixed [15–22].
For both benzodiazepines and anticholinergics, several
methodological biases exist in the published studies in-
cluding first the lack of longitudinal observational win-
dow with a clear baseline measurement of cognitive and
functional status of the population at risk; second the
absence of gold standard measurement of the dementia
incidence; third, no precise baseline measurement of the
exposure variable (benzodiazepine and anticholinergic
use); and finally the limitation of observational studies in
resolving protopathic bias, whereby medication use
might be prescribed for symptoms at the very early
stages of dementia, inducing an association between
medication use and later dementia diagnosis.
We have previously demonstrated association between
cognitive decline and anticholinergic use between base-
line and 2-year follow-up assessments of the Medical Re-
search Council Cognitive Function and Ageing Study
(MRC CFAS) [9]. Here we extend this analysis to exam-
ine dementia incidence at 10 year follow-up, with respect
to patterns of anticholinergic and benzodiazepine use at
the baseline and 2-year follow-up assessments.
Methods
Setting
The MRC CFAS is a population based, prospective, mul-
ticentre cohort study in England and Wales specifically
designed to estimate the prevalence, risk factors and
course of dementia. The study design has been described
elsewhere [23]; (see also www.cfas.ac.uk for full details).
In brief, 13,004 participants, age 65 and older, from
Cambridgeshire, Gwynedd, Newcastle, Nottingham and
Oxford, were recruited with baseline interviews (Y0) con-
ducted between 1991 and 1993. All individuals still alive
and traceable were invited to be re-interviewed at two
years (Y2) and 10 years (Y10) after baseline. At each wave,
participants were questioned about sociodemographic
factors, lifestyle, physical and mental health (including
self-reported insomnia, measures of anxiety and depres-
sion) and completed a cognitive battery and in-home
medication inventory. For the present analysis, we in-
cluded all those who participated at Y2 with no study
diagnosis of dementia at Y0 or at Y2, and measured inci-
dent dementia as an outcome at Y10.
Outcome assessment
At Y0 and Y2 the study diagnosis of dementia was made
using a two-phase process (Fig. 1). An initial screening
interview was administered to all participants. A strati-
fied subsample of 20%, including all of those with cogni-
tive impairment, but also including healthy participants
then underwent a thorough assessment using the Auto-
mated Geriatric Examination for Computer Assisted
Taxonomy (AGECAT) algorithm to make a study diag-
nosis of dementia [23–26]. AGECAT produces a score
of between 0 and 5. Dementia was defined as AGECAT
scores ≥3 which is equivalent to dementia as diagnosed
by DSM-III-R [24]. All surviving participants underwent
the full assessment at Y10.
For those who underwent a screen interview but were
not selected to undergo the assessment we imputed the
Y2 dementia status based on cognitive screen scores
(using a multiple imputation). This procedure identified
that there were possibly a small number of cases of de-
mentia among the screen-only sample, but these were
only very rarely seen among those surviving Y10 sample.
Hence our primary analysis assumed no prevalent de-
mentia cases among the Y2 screen-only participants;
participants who were imputed to have dementia at
baseline were excluded in a sensitivity analysis.
Medication exposures
During each interview participants were asked to provide
details of all medication currently being used, either pre-
scribed or bought over-the-counter. These were re-
corded using UK National Health Service Read codes.
Packaging was checked and proxy respondents supplied
medication information if participants were unable to do
so. Previous studies in older population have demon-
strated self-reported medication data gathered in this
way to be mostly in moderate-good agreement with pre-
scription data records [27].
All medications were coded according to the Anti-
cholinergic Cognitive Burden (ACB) scale [28]. In sum-
mary, medications with serum anticholinergic activity or
in vitro affinity to muscarinic receptors but with no
known clinically relevant negative cognitive effects are
scored 1 on the scale, while drugs with established and
clinically relevant anticholinergic effects are scored 2
based on blood-brain penetration and 3 if also have re-
ported associations with delirium. All other drugs are
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scored 0. Very few medications were classed as having
an ACB score of 2, so we created binary exposure vari-
ables for ACB12 (use of any medications scoring 1 or 2)
and ACB3 (use of any medications scoring 3). A total
ACB sum score, and a variable corresponding to the
sum of ACB12 drugs only was also created. Each of
these exposures was determined independently at Y0
and Y2.
Similarly for benzodiazepines, a binary variable (BZD)
corresponding to taking any benzodiazepine or non-
benzodiazepine derivative (hypnotics such as zopiclone
also known as Z-drugs) was created at both Y0 and Y2.
For each group (BZD, ACB12 and ACB3) participants
were then classified as being an ‘ever-user’ (if there was
any use at Y0 or Y2), and then sub-classified as a ‘recur-
rent user’ (use at Y0 and Y2), new user (only at Y2), or
as a discontinuing user (only at Y0).
Covariates
We selected covariates that might have a confounding
effect between the use of benzodiazepines or anticholin-
ergics and incident dementia. We included demographic
variables of sex, age, education (≤ 9 years, ≥ 10 years), so-
cial class (measured by prior occupation as manual vs
non manual), centre of recruitment, and study arm
(screen or assessment), variables that are indicators for
ACB3 or BZD use, early symptoms of dementia or
known to be associated with dementia (reporting having
suffered stroke, Parkinson disease, epilepsy, sleep prob-
lems, anxiety, depression or being diagnosed depression
at either Y0 or Y2, as binary variables), self- reported
health (excellent/good; fair/poor) at Y2 and cognition re-
lated variables.
Pre-existing cognitive impairment and ongoing cogni-
tive decline are the most important potentially confound-
ing factors, these were measured by the Mini-Mental State
Examination (MMSE) at Y2 (≤25, > 25), the decrease in
MMSE scores between Y0 and Y2 (< 1, 1, 2, ≥ 3 points),
the MMSE orientation sub-score at Y2 (< 9, 9/10) and
self-perceived change in memory function between re-
cruitment and 2 years (No change or better vs worse). Dis-
ability at Y2 was classified using the Townsend disability
scale as either no impairment, any impairment in instru-
mental activities of daily living or any impairment in basic
activities of daily living [29].
Statistical analyses
Separate univariable Poisson regression models with
Huber-White robust standard errors were used to esti-
mate incidence rate ratios (IRR) for the association be-
tween each potential predictor variable and incident
dementia at Y10 [30]. 95% confidence intervals are re-
ported for all estimates.
In multivariable analysis we additionally included each
of the three ever-use variables (where they were not the
exposure of interest) and the demographic, health and
cognition related variables mentioned above.
We carried out pre-planned stratified analyses of the
main ‘ever-use’ models by year of birth (≤1919 vs 1920
onwards), sex and MMSE score at Y2 (> 25, ≤25). The
Fig. 1 Flow of participants included in the current analysis through the MRC Cognitive Function and Ageing Study. See www.cfas.ac.uk for the
full design of the Cognitive Function and Ageing Studies
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threshold for cognitive function and age were chosen as
they reflect the stratification of the original CFAS study
sampling.
As expected in this population there was substantial
loss to follow-up between Y2 and Y10 caused by drop
out and death. Inverse probability weights were used to
adjust for non-response at Y10 and loss of contact be-
tween Y2 and Y10 or refusal to participate at Y10, con-
ditional on having survived. These weights were
calculated using a logistic regression model for being
successfully re-assessed at Y10 (conditional on surviving
to Y10) including the main effects of all exposures (BZD,
ACB12 and ACB3), covariates and the interactions be-
tween exposures and sex and MMSE at Y2.
STATA 14.1 was used for all analysis.
Sensitivity analyses
We carried out three sensitivity analyses to test the im-
pact of modelling assumptions or analytical choices on
our results. First, we excluded potentially mediating or
colliding variables: MMSE at Y2, change in MMSE (Y0
to Y2), MMSE orientation sub-score at Y2, disability,
and arm of the study. Second, we used multiple imput-
ation to identify screen-only participants with dementia
at baseline based on their demographic information and
cognitive scores as described above, and excluded them
from each imputed analysis. Finally, we took into ac-
count the possibility that higher mortality rates among
older people taking anticholinergics or benzodiazepines
and related medications might suppress our estimates of
dementia incidence in this group via inverse probability
weights calculated using on the probability of death or
drop-out (rather than drop-out alone) between Y2 and
Y10 based on baseline factors.
Results
See Fig. 1 for participant flow through the study. From
the 13,004 participants recruited to MRC CFAS at Y0,
8216 were interviewed at Y2, did not have dementia or
unknown dementia status at Y2 and so form the baseline
sample for our incidence analysis. Of these, 3136 died
and 1990 were lost to follow up before Y10. At Y10, we
excluded a further 5 participants classified as having de-
mentia at Y0 but not Y10 and 45 with unknown demen-
tia status at Y10, leaving 220 people with incident
dementia and 2825 people without incident dementia in-
cluded in the study.
Table 1 shows participant characteristics stratified by
follow-up status. Those who developed dementia by Y10
were older, had lower cognitive function at Y2 (mean
MMSE 24 vs 27), more disability (ADL-IADL 22% vs
7%), fewer years of education (≥ 10 years 29% vs 44%)
and were substantially more likely to report worsening
memory from recruitment to 2-year follow up (49% vs
27%) and poorer health (32% vs 21%).
Medication use
A breakdown of baseline exposures by 10-year follow-up
status is shown in Table 1. Full details of drug use are in
Additional file 1. Among those surviving to 10 years,
7.5% reported ever use of a BZD (short-acting 4.2%,
long-acting 3.7%). Hypnotic BZD were used by 5.9%
with 1.9% using anxiolytics. The most commonly re-
ported BZDs were Temazepam (47% of BZDs reported),
Nitrazepam (30%) and Diazepam (15%). Non-
benzodiazepine Z-drug use was rare in this cohort
(prevalence of 0.4%).
Use of ACB3 at baseline or 2-year follow-up was re-
ported by 5.6% of the surviving sample; 2.3% were recur-
rent users. The majority of ACB3 drugs were
antidepressants (3.8% of the surviving sample; correspond-
ing to 69% of ACB3 medications), urologicals (0.7% re-
ported ever use among the sample), gastrointestinal (0.6%),
antipsychotics (0.5%), antihistamines (0.3%) and Parkinson-
ian drugs (0.1%). The most common ever-use ACB3 medi-
cations were the antidepressants: amitriptyline (22% of
ACB3) and dosulepin (22% and of ACB3).
In total, 53% of the surviving sample reported ACB1
or ACB2 at baseline or 2-year follow-up, with 34%
reporting ACB1 or ACB2 use at both waves.
Although Y10 medication is not considered an expos-
ure in our study, we compared Y10 to Y0 and Y2 medi-
cation to understand to what extent medication use was
likely to have continued in the overall study sample.
Medication use at Y10 was highly correlated with use at
Y0 and Y2 (see Additional file 2) with around 60% of ‘re-
current’ users at Y0 and Y2 reported use of each class at
Y10. This suggests that in many cases use at Y0 and Y2
is likely to reflect repeated use during the follow-up
period as opposed to being one-off exposures.
Dementia incidence
Table 2 describes incident dementia in our sample as
well as the unadjusted and adjusted incidence rate ratios
(aIRR). After weighting, 9.5% (N = 220) of participants
had a study diagnosis of dementia at Y10; 14.5, 15.4 and
10.5% for BZD, ACB3, ACB12 ever-users and 16.0, 18.6
and 10.7% for recurrent users, respectively.
Adjusted IRRs for dementia at Y10 were 1.06 (95%CI
0.72, 1.60) for any BZD use, 1.28 (95% CI 0.82, 2.00) for
any ACB3 and 0.89 (95%CI 0.68 1.17) for any ACB12
use. Recurrent use was associated with IRRs of 1.30
(95%CI 0.79, 2.14) for BZD, 1.68 (95%CI 1.00, 2.82) for
ACB3 and 0.95 (95%CI 0.71, 1.28) for ACB12.
There was no evidence for an increase in dementia
risk with increasing total ACB score at each wave, or
with the number of ACB1 or ACB2 medications used.
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Table 1 Participant characteristics stratified by Y10 follow-up status and dementia outcome
Characteristic Dementia at Y10
(n = 220)
No dementia at Y10
(n = 2825)
Lost to follow up between Y2 and
Y10 (n = 1990)
Died between Y2 and Y10
(n = 3136)
Female 163 (77.3) 1675 (61.2) 1315 (66.1) 1630 (52.0)
Mean age (SD) 77.1 (7.0) 72.0 (10.0) 73.8 (6.1) 76.9 (6.7)
Educated for ≥ 10 years 68 (29.3) 1311 (43.9) 754 (37.9) 1127 (35.9)
Manual occupation 132 (61.7) 1359 (50.1) 1088 (54.7) 1751 (55.8)
CFAS assessment arm 84 (51.0) 594 (27.4) 814 (40.9) 999 (31.9)
Y2 MMSE
≤ 21 30 (22.6) 57 (3.5) 190 (9.6) 381 (12.2)
22–25 76 (38.4) 432 (20.0) 552 (27.7) 845 (27)
26–30 114 (39.0) 2336 (76.5) 1196 (60.1) 1847 (58.9)
Decline in MMSE between Y0 and Y2
No decline / improvement 100 (41.1) 1592 (55.0) 988 (49.6) 1444 (46.0)
1 point 34 (13.1) 529 (17.6) 302 (15.2) 487 (15.5)
2 points 34 (13.6) 350 (11.8) 220 (11.1) 364 (11.6)
≥ 3 points 50 (29.0) 326 (14.2) 402 (20.2) 729 (23.2)
Disability
None 121 (47.1) 2336 (80.0) 1386 (69.6) 1562 (49.8)
IADL impairment 65 (30.2) 350 (13.1) 331 (16.6) 672 (21.4)
ADL impairment / unclassified 34 (22.7) 139 (7.0) 273 (13.7) 902 (28.8)
Self-reported memory decline
(Y0 to Y2)
110 (48.7) 774 (27.4) 592 (29.7) 1152 (36.7)
Fair/poor self-reported health 66 (31.7) 529 (21.2) 523 (26.3) 1174 (37.4)
Comorbiditya
Sleep disturbance 56 (26.5) 606 (22.6) 507 (25.5) 902 (28.8)
Diagnosed depression 22 (11.0) 309 (11.3) 216 (10.9) 290 (9.2)
Consulted GP for depression 31 (15.8) 388 (14.4) 282 (14.2) 387 (12.3)
Consulted GP for anxiety 28 (11.8) 242 (8.5) 186 (9.3) 228 (7.3)
BZD useb
None 195 (86.6) 2623 (91.7) 1763 (88.6) 2726 (86.9)
Any e 25 (13.5) 202 (8.3) 222 (11.2) 391 (12.5)
New f 5 (2.2) 43 (1.9) 49 (2.5) 92 (2.9)
Discontinuing g 6 (3.2) 51 (2.0) 57 (2.9) 95 (3.0)
Recurrent h 14 (8.1) 108 (4.4) 116 (5.8) 204 (6.5)
ACB3 usec
None 198 (89.8) 2677 (94.1) 1842 (92.6) 2831 (90.3)
Any e 22 (10.2) 148 (5.9) 143 (7.2) 286 (9.1)
New f 5 (1.8) 55 (2.2) 58 (2.9) 112 (3.6)
Discontinuing g 5 (3.6) 35 (1.5) 43 (2.2) 78 (2.5)
Recurrent h 12 (4.9) 58 (2.2) 42 (2.1) 96 (3.1)
ACB12 used
None 85 (41.0) 1353 (47.3) 908 (45.6) 972 (31)
Any e 135 (59.0) 1472 (52.7) 1077 (54.1) 2145 (68.4)
New f 34 (16.0) 321 (11.4) 210 (10.6) 419 (13.4)
Discontinuing g 11 (4.5) 209 (7.9) 175 (8.8) 327 (10.4)
Recurrent h 90 (38.5) 942 (33.5) 692 (34.8) 1399 (44.6)
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Number of participants (percentages) given unless specified otherwise. Percentages of participants at Y10 are weighted for attrition due to non-response at Y10
and loss of contact between Y2 and Y10
Abbreviations: CFAS Cognitive Function and Ageing Study, SD standard deviation, MMSE Mini-Mental State Examination, IADL Instrumental Activities of Daily
Living, ADL Activities of Daily Living, GP General Practitioner
aAny record of specific comorbidity at the Y0 or Y2 assessment
bUse of benzodiazepines or Z-drugs
cUse of drugs scoring 3 on the Anticholinergic Cognitive Burden scale
dUse of drugs scoring 1 or 2 on the Anticholinergic Cognitive Burden scale
e-hDrug use categories are
None: no use at Y0 or Y2;
Any: Use at Y0 or Y2;
New: Use at Y2 but not Y0
Discontinuing: Use at Y0 but not Y2
Table 2 Attrition-weighted unadjusted and multivariable adjusted incidence rate ratios for the association between benzodiazepine
and anticholinergic medication use and incident dementia
Exposure and pattern
of use
Dementia incidence Unadjusted
IRR (95% CI)
Adjustedb IRR
(95% CI)Cases Total %a
BZD use
None 195 2819 9.0 1 (Ref.) 1 (Ref.)
Any 25 227 14.5 1.61 (1.06,2.46) 1.06 (0.72,1.60)
New 5 48 11.1 1.23 (0.51,2.96) 0.65 (0.27,1.60)
Discontinuing 6 57 14.1 1.57 (0.74,3.35) 1.06 (0.53,2.14)
Recurrent 14 122 16.0 1.78 (1.02,3.12) 1.30 (0.79,2.14)
ACB3 use
None 198 2876 9.1 1 (Ref.) 1 (Ref.)
Any 22 170 15.4 1.70 (1.09,2.65) 1.28 (0.82,2.00)
New 5 60 7.9 0.88 (0.37,2.09) 0.87 (0.34,2.22)
Discontinuing 5 40 20.1 2.22 (0.96,5.14) 1.19 (0.53,2.68)
Recurrent 12 70 18.6 2.05 (1.18,3.56) 1.68 (1.00,2.82)
ACB3 subclass
Not antidepressants 6 53 13.6 1.50 (0.68,3.32) 1.74 (0.84,3.62)
Antidepressants 16 117 16.1 1.78 (1.06,2.98) 1.16 (0.69,1.94)
ACB1 or ACB2 use
None 85 1438 8.3 1 (Ref.) 1 (Ref.)
Any 135 1609 10.5 1.26 (0.95,1.67) 0.89 (0.68,1.17)
New 34 355 12.8 1.54 (1.02,2.33) 1.14 (0.79,1.63)
Discontinuing 11 220 5.6 0.68 (0.36,1.27) 0.36 (0.19,0.69)
Recurrent 90 1033 10.7 1.29 (0.95,1.75) 0.95 (0.71,1.28)
ACB sum score
Total ACB score (per point) 1.07 (1.03,1.13) 1.00 (0.94,1.06)
ACB12 score (per point) 1.06 (1.00,1.13) 0.97 (0.90,1.04)
ACB3 score (per point) 1.10 (1.02,1.19) 1.06 (0.98, 1.15)
Abbreviations: IRR Attrition-weighted unadjusted incidence rate ratio, aIRR Attrition-weighted adjusted incidence rate ratio, CI confidence-interval, ACB
Anticholinergic Cognitive Burden, ACB1 use of a medicine with an ACB score of 1. Scores correspond to possibly anticholinergic (score 1) probably anticholinergic
(score 2) definitely anticholinergic (score 3)
a% represents weighted incidence
bAdjusted for sex, age, education (≤ 9 years, ≥ 10 years), social class (manual vs non manual), residential accommodation, centre of recruitment, study arm (screen
or assessment), health conditions at Y0 or Y2 (stroke, Parkinson disease, epilepsy, sleep problems, anxiety, depression), self- reported health (excellent/good; fair/
poor) at Y2, Disability at Y2 (no impairment, impairment in instrumental activities of daily living, or impairment in basic activities of daily living), Mini-Mental State
Examination (MMSE) at Y2 (≤25, > 25), MMSE orientation sub-score at Y2 (< 9, 9/10), decrease in MMSE score between Y0 and Y2 (< 1, 1, 2, ≥ 3 points), and self-
perceived change in memory function between Y0 and Y2 (No change or better vs worse)
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No significant association was found between dementia
and ever-use of short or medium-acting, long-acting,
hypnotic or anxiolytic BZDs, or for anti-depressant or
‘other’ anticholinergics although numbers in these sub-
groups were small (results not shown).
Stratified analysis
Stratified analyses are shown in Table 3. The effect of
ACB3 was restricted to those with good baseline cogni-
tive function (ever-users aIRR: 2.28, 95%CI 1.32, 3.92),
whereas no such association was seen among the group
with impaired cognition (ever-users aIRR: 0.94, 95% CI:
0.51–1.73). Those with poor cognitive function (MMSE
≤25 at Y2) had a dementia incidence rate of around 21%
irrespective of anticholinergic use (21.3%; 97 of 500
among never-users vs 21.8%; 9 of 46 for ever-users),
while for those with good cognitive function (MMSE> 25
at Y2) the Y10 dementia incidence rate was 11.1% (13 of
124) for ACB3 ever-users and 4.7% (101 of 2326) for
never-users (Additional file 3). This is supported by a
statistically significant interaction effect (p = 0.02). No
other significant subgroup differences were found.
Sensitivity analyses
Results from the sensitivity analyses are shown in Add-
itional file 4. No changes were seen after removing im-
puted possible dementia cases at baseline or 2-year
follow-up. However, after excluding baseline disability
and cognition related variables from multivariable re-
gression there was an increase in the effects of any
ACB3 use and recurrent use with aIRRs 1.55 (95%CI
1.04, 2.32) and 2.02 (95%CI 1.21, 3.39), respectively. No
main changes were observed when using weights to ad-
just for mortality or after carrying out a competing risk
analysis (results not shown). In analysis stratified by cog-
nitive score, there is no change to main findings in sen-
sitivity analysis; for example when using inverse
probability weights to adjust for attrition by death or
other loss to follow up the association between baseline
ACB3 use and incident dementia among those with
MMSE> 25 at Y2 is aIRR = 2.24 (95% CI: 1.24–4.06)
compared to IRR = 1.01 (0.55–1.87) among those with
Y2 MMSE< 25.
Discussion
In a cohort study with 10-year follow-up we did not find
any evidence of an increase in risk of dementia associ-
ated with the use benzodiazepines or anticholinergics
scoring ACB1 or ACB2. We did find a statistically sig-
nificant increase in dementia risk among recurrent users
of ACB3 anticholinergics and also an association be-
tween ACB3 anticholinergics use and dementia risk
among the subgroup with good baseline cognitive func-
tion, suggesting that effects might more apparent in dif-
ferent subgroups of the older population.
Benzodiazepines
Previous studies on the effect of benzodiazepines have
been inconsistent, with some large and apparently high
quality studies showing a clear effect of benzodiazepine
use on dementia incidence [16–18, 20, 21], but others
finding no effect [15, 19, 22]. There is no readily appar-
ent difference between these studies in design that ex-
plains this inconsistency, although possible explanations
include selection biases into electronic health record da-
tabases, differing methods of ascertaining benzodiazep-
ine use, such as duration, dose and chronicity and the
measurement of dementia outcome [15], or the differing
profile of benzodiazepine use [31], population character-
istics across studies or the manner in which each study
was able to control for covariates. There was insufficient
use of Z-drugs among our cohort to draw any conclu-
sions regarding their effects on dementia incidence.
Strong anticholinergics
Our estimate of the effect of ACB3 anticholinergics on
dementia incidence was not statistically significant, but
is consistent with recent effect estimates from analyses
Table 3 Attrition-weighted adjusted incidence rate ratios for benzodiazepine and anticholinergic medication use and incident
dementia, stratified by cognition, sex and age
Incidence rate ratio (95% confidence interval) by exposure
Subgroup Any Benzodiazepines Any ACB3 Any ACB12
MMSE at Y2 > 25 0.72 (0.35,1.50) 2.28 (1.32,3.92)* 0.99 (0.68,1.43)
MMSE at Y2 ≤ 25 1.23 (0.74,2.06) 0.94 (0.51,1.73) 0.78 (0.54,1.12)
Male 0.29 (0.06,1.31) 2.06 (0.78,5.46) 1.11 (0.66,1.89)
Female 1.17 (0.77,1.78) 1.24 (0.77,2.01) 0.85 (0.63,1.16)
Younger (born 1920–1929) 1.31 (0.52,3.27) 1.16 (0.45,3.01) 1.57 (0.82,3.00)
Older (born before 1920) 1.06 (0.69,1.61) 1.27 (0.78,2.09) 0.77 (0.58,1.03)
*p < 0.01
Abbreviations: MMSE Mini-Mental State Examination, ACB Anticholinergic Cognitive Burden, ACB12 use of a medicine with an ACB score of 1 or 2. Scores
correspond to possibly anticholinergic (score 1), probably anticholinergic (score 2) and definitely anticholinergic (score 3). Number of observations and adjusted
percentage in each group are reported in Additional file 3
Grossi et al. BMC Geriatrics          (2019) 19:276 Page 7 of 10
of electronic medical records [7, 32]. However, in
planned subgroup analyses we observed a borderline sig-
nificant increased dementia risk in recurrent users of
ACB3 anticholinergics, defined as those participants who
reported anticholinergic use at both baseline and two-
year follow-up, more likely to reflect a longer term or
continuous anticholinergic load. This is consistent with
the hypothesis that long-term as opposed to one-off use
is needed to increase dementia risk.
Consistent with our work, previous studies have con-
sistently reported associations between anticholinergic
use and dementia incidence, with a greater effect seen
among prevalent (as opposed to new users) or long-term
recurrent users, with some studies reporting a dose ef-
fect with increasing risk at higher doses [7, 32]. New use
or short term use has consistently not been associated
with risk of developing dementia [8]. Similar results have
been observed for studies focussing on cognitive change
instead of dementia or MCI outcomes and in neuropath-
ology studies [33, 34].
We stratified our analysis by baseline cognitive func-
tion to test the hypothesis that the effect is only seen
among people with an existing cognitive impairment,
reflecting possible protopathic bias. In fact the reverse
was observed, the effect was restricted to those with
good baseline cognitive function. It is possible that this
reflects increased attrition among the more cognitively
frail using anticholinergics, however this finding is not
affected by using a weight that corrects for attrition due
to death, and in any case this results demonstrates that
the increase in dementia incidence associated with anti-
cholinergics is not restricted to those with existing cog-
nitive impairment or those with incipent dementia.
Anticholinergics represent a broad class of medica-
tions that act on different systems, and it is possible that
different anticholinergics have different long term effects
on brain health [12]. Disaggregation of anticholinergic
classes may also help to identify possible confounding by
indication or protopathic bias. Our study suggests that
anticholinergics other than antidepressants have a stron-
ger link with incident dementia than do anticholinergic
antidepressants after adjustment for confounding factors,
but owing to small numbers estimates of the effects of
subclasses are very imprecise [7, 12].
Anticholinergics with score of 1 or 2
While ACB3 anticholinergics are used by only 3–5% of
the older population at any time, up to 50% are using
one or more of the much wider group that are consid-
ered ‘possibly’ anticholinergic (score of 1), and any effect
of these medications on dementia incidence would have
a great public health significance [9]. Our finding that
the number of ACB12 anticholinergics used is not asso-
ciated with future incident dementia agrees with our
previous analysis of cognitive change between baseline
and 2 years [9] and previous studies that have considered
these groups separately [12, 35, 36]. The number of
medications classified as ACB2 is very small and this ef-
fect estimate is largely dominated by the effect of medi-
cations classified ACB1. Findings from the Baltimore
Longitudinal Study of Ageing suggest an increase in the
risk of ‘Alzheimer’s disease or MCI’ with increasing use
of ‘possible’ anticholinergics, with an associated increase
in cortical atrophy, although there was no effect of defin-
ite anticholinergic (score of 3) use suggesting that anti-
cholinergic properties of these drugs may not underlie
the effect [37].
Strengths and limitations
Our study has several important strengths and limita-
tions. By using the first two waves of MRC CFAS (years
0 and 2) as the baseline and dementia at 10-year follow-
up as the outcome we could identify the long-term effect
of different patterns of uses of medications in a
population-representative cohort. We did not measure
medication use or dementia diagnoses occurring be-
tween assessments, or the diagnoses for those who
dropped out before Y10. Although the high concordance
between medications used at Y0, Y2 and Y10 suggests
that use may have been continual during the follow up
period in many cases, we have no direct evidence for
this. Medication use was based on self-report and adher-
ence was not formally assessed; although there is no gold
standard method for measuring adherence to medication
[38]. Dementia was measured using a validated algo-
rithm, and thus any bias due to outcome ascertainment
is reduced compared to studies relying on a recorded
diagnosis dementia which will significantly under repre-
sent true dementia incidence [39].
Despite the large sample size of MRC CFAS (n = 13,004),
the numbers using benzodiazepines or anticholin-
ergics with score ACB3 during the first two waves and
developing incident dementia by Y10 are relatively small.
Estimating effects for subgroups is difficult. Attrition
over 8 years was typical of that seen in comparable stud-
ies of ageing, and we applied inverse probability weight-
ing based on exposures and baseline cognitive scores to
adjust for differential drop-out. Use of inverse probabil-
ity weights assumes that loss to follow-up or death was
not differential with respect to unmeasured confounders
or to the outcome. Our findings might be biased if the
interaction between medication use and dementia has a
specific association with drop-out that could not be at-
tributed to either factor alone or the interaction between
exposure and pre-existing cognitive impairment.
We controlled for many relevant potential con-
founders, in particular for many of the indications for
anticholinergics and benzodiazepines. We could not
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control for urinary incontinence or obesity as this was
not routinely recorded, however the anticholinergic uro-
logicals were rarely used among this cohort. Mental
health disorders apart from depression and anxiety were
also not routinely recorded. Adjusting for recent cogni-
tive decline and observing the effect among those with
good cognitive function at Y2 helps to exclude the possi-
bility of protopathic bias due to reverse causation.
Conclusions
We found no evidence that benzodiazepines are associated
with dementia incidence but we cannot rule out an effect
as the number of benzodiazepine users in our study was
relatively small. Consistent with previous studies we found
an increase in dementia incidence associated with the re-
current use of anticholinergics with an ACB score of 3,
particularly among those with good baseline cognitive
function. This should be treated with caution owing to
small sample size but when considered alongside the
growing body of evidence from cohort studies and admin-
istrative data sources suggests that at least some anti-
cholinergic medications could increase the risk of future
dementia. The prevalence of anticholinergic medication
use remains high among middle aged and older people,
making this a potentially important modifiable risk factor
for dementia. Future research should focus on more care-
fully establishing the mechanism by which this occurs,
whether the effect is reversed by medication cessation and
whether specific anticholinergic medication or classes of
medication confer the greatest risk and among which sub-
groups of the population.
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